News coverage about AnaptysBio (NASDAQ:ANAB) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AnaptysBio earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.7839036988075 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of AnaptysBio (NASDAQ:ANAB) opened at $87.84 on Monday. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $90.80. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. equities research analysts expect that AnaptysBio will post -1.72 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Tuesday, August 22nd. Wedbush reiterated a “positive” rating and set a $82.00 price objective (up from $75.00) on shares of AnaptysBio in a research report on Tuesday, November 7th. Stifel Nicolaus reiterated a “buy” rating and set a $35.00 price objective on shares of AnaptysBio in a research report on Tuesday, September 12th. Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Credit Suisse Group increased their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 10th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. AnaptysBio has an average rating of “Buy” and a consensus target price of $84.78.
COPYRIGHT VIOLATION NOTICE: This story was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.truebluetribune.com/2017/12/11/anaptysbio-anab-receives-daily-news-impact-rating-of-0-06.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.